Advancing Medicine. Precisely.

Customized phage therapies to eradicate
harmful bacteria in chronic diseases

Learn More

Our Solution

BiomX is developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as cystic fibrosis, inflammatory bowel disease, atopic dermatitis and colorectal cancer. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.

Learn More

Understanding
Bacteriophage

Phage Therapy and
the bolt Platform

xmarker Biomarker
Discovery

Led by
world-leading scientists

Our technological platform for the discovery and development of phage therapies originates from the labs of world-leading scientists from the Weizmann Institute of Science and MIT.

Meet Our Team

Our Pipeline

Learn More

Phage Discovery

Pre-Clinical

Phase I

Phase II

Phase III

Acne BX001 Phase I

IBD/PSC BX003 Phase I

Cystic Fibrosis Pre-Clinical

Atopic Dermatitis Phage Discovery

Colorectal Cancer Phage Discovery

Learn More

Partners

News and Events

View All

Press Releases Feb 02, 2021 BiomX Announces Positive Results of a Phase 1a Pharmacokinetic Study for Inflammatory Bowel Disease/Primary Sclerosing Cholangitis (IBD/PSC) Evaluating Delivery of Oral BX002 Phage Therapy

Press Releases Jan 04, 2021 BiomX to Present at Upcoming January Investor Conferences

Events Mar 25, 2021 3rd Bacteriophage Therapy Summit

View All

Join Our Team

At BiomX, we value each and every individual. By working with us, our employees harness their talent and cultivate our company with innovation, purpose, and growth. Come be a part of our cutting-edge team of innovators, scientists, and game-changers on a mission to develop the most advanced phage therapeutics.